September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Determining the therapeutic window of non-damaging retinal laser therapy by protein expression
Author Affiliations & Notes
  • Jenny Wang
    Applied Physics, Stanford University, Stanford, California, United States
  • Daniel Lavinsky
    Ophthalmology, Federal University Rio Grande do Sul, Porto Alegre, Brazil
  • Philip Huie
    Ophthalmology, Stanford University, Stanford, California, United States
    Hansen Experimental Physics Laboratory, Stanford University, Stanford, California, United States
  • Roopa Dalal
    Ophthalmology, Stanford University, Stanford, California, United States
  • Dae Yeong Lee
    Ophthalmology, Gachon University Gil Medical Center, Incheon, Korea (the Republic of)
  • Seung Jun Lee
    Ophthalmology, Kangwon National University, Chuncheon, Korea (the Republic of)
  • Daniel V Palanker
    Ophthalmology, Stanford University, Stanford, California, United States
    Hansen Experimental Physics Laboratory, Stanford University, Stanford, California, United States
  • Footnotes
    Commercial Relationships   Jenny Wang, None; Daniel Lavinsky, Topcon Medical Laser System (C); Philip Huie, None; Roopa Dalal, None; Dae Yeong Lee, None; Seung Jun Lee, None; Daniel Palanker, Topcon Medical Laser System (C), Topcon Medical Laser System (P)
  • Footnotes
    Support  Stanford Photonics Research Center
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5845. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jenny Wang, Daniel Lavinsky, Philip Huie, Roopa Dalal, Dae Yeong Lee, Seung Jun Lee, Daniel V Palanker; Determining the therapeutic window of non-damaging retinal laser therapy by protein expression. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5845.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : “Sub-threshold” laser therapy has been used in several configurations to treat macular disorders with promising but inconsistent results and unknown therapeutic mechanism. In this study, we use a titration algorithm, Endpoint Management (EpM), to deliver specified thermal dose to the retina and define the therapeutic window for non-damaging laser therapy by measuring the thresholds of (a) cellular toxicity and (b) expression of heat shock protein (HSP70) and glial fibrillary acidic protein (GFAP).

Methods : Dutch-belted rabbits (n=15) were irradiated with a 577 nm PASCAL laser using the EpM titration algorithm to set experimental pulse energies relative to a barely visible lesion. Grids of laser spots at 20, 25, 30, 40, 100 and 114% energy settings were applied and the RPE was analyzed at 7 hours after laser application using live/dead staining and whole-mount immunostaining for HSP70. Histology (t = 1 day) and scanning electron microscopy (t = 1 hr) were also performed to confirm damage threshold. Immunohistochemistry for GFAP (t = 1 month) was used to measure long-term glial cell activation. Results were compared to a computational model of the retinal heating.

Results : Energy setting of 30% (n = 250) was non-damaging while 40% (n =250) was damaging in 69% of laser spots. HSP expression in the retinal pigment epithelium (RPE) was observed at 25% energy and above, with activated area at 30% measured as 0.75 (0.62 – 1.02) mm2 per 100 spots. HSP expression area increased through 40%, but at higher settings, the HSP expressing cells appeared only at the edges of the central damage zone. Our computational model matched experimentally observed HSP expression patterns for cells where Arrhenius integral was in the non-damaging therapeutic window (0.1< Ω < 1). Activation of GFAP in Muëller cells 1 month after the laser treatment was observed with energy settings of 30% and higher.

Conclusions : Retinal laser therapy with 30% energy on EpM scale can avoid tissue damage within normal variations of pigmentation and it activates two different types of tissue response: heat shock protein expression in the RPE and activation of Müller cells in the retina. Lack of tissue damage allows (a) macula therapy at much higher spot density than conventional photocoagulation, which should boost clinical efficacy, (b) treatment of the fovea, and (c) periodic retreatment in chronic diseases.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×